Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors-Reference-Cited by-同舟云学术

Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors

Published:2015-01 Issue:1 Volume:11 Page:47-54
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Weycker Derek¹,Li Xiaoyan¹,Edelsberg John¹,Barron Rich¹,Kartashov Alex¹,Xu Hairong¹,Lyman Gary H.¹

Affiliation:

1. Policy Analysis (PAI), Brookline, MA; Amgen, Thousand Oaks, CA; and Hutchinson Cancer Research Center, Seattle, WA

Abstract

Among patients receiving myelosuppressive chemotherapy for metastatic cancer in US clinical practice, febrile neutropenia is a frequent complication associated with morbidity, mortality, and economic costs.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2014.001492

Reference31 articles.

1. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

2. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

3. Risk of mortality in patients with cancer who experience febrile neutropenia

4. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

5. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data;Supportive Care in Cancer;2024-09-13

2. Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer;Frontiers in Oncology;2024-08-19

3. The role of G-CSF in the prevention of cytostaticassociated adverse events during antitumor drug therapy;Meditsinskiy sovet = Medical Council;2024-07-25

4. Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy;JCO Oncology Practice;2024-07-24

5. A retrospective study on the analysis of influencing factors of neutropenia in endometrial cancer with adjuvant chemoradiotherapy;Radiation Oncology;2024-06-18